vaccine safety

Efficacy and safety of SARS-CoV-2 vaccination in pregnancy to prevent COVID-19 in mothers and early infancy. This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the effects of SARS-CoV-2 vaccination during pregnancy, versus placebo or no vaccination during pregnancy, for preventing COVID-19 disease in mothers and infants.

. Health and social care 3. Public health 4. Health protection 5. Immunisation Guidance Safety of COVID-19 vaccines when given in pregnancy Guidance for health professionals to share with pregnant women immunised with COVID-19 vaccines.From: UK Health Security Agency Published 18 December 2020 Last updated 30 April 2021 — See all updates Get emails about this page DocumentsThe safety of COVID-19 Safety of COVID-19 vaccines when given in pregnancy Safety of COVID-19 vaccines when given in pregnancy - GOV.UK Skip to main content Cookies on GOV.UKWe use some essential cookies to make this website work.We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.We also use cookies set by other sites to help us deliver content

Vaccine safety and adverse events following immunisation: the green book, chapter 8 Vaccine safety and adverse events following immunisation: the green book, chapter 8 - GOV.UK Cookies on GOV.UKWe use some essential cookies to make this website work. We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services. We also use cookies releases and corporate reports Search Search GOV.UK Search 1. Home 2. Health and social care 3. Public health 4. Health protection 5. Immunisation Guidance Vaccine safety and adverse events following immunisation: the green book, chapter 8 Information for public health professionals on immunisation. From: UK Health Security Agency Published 20 March 2013 Last updated 22 November 2024 — See all updates

Is there an impact of sex (biologically male/female) differences between donors and recipients on safety and efficacy of cell therapies for immune system and autoimmune conditions? Skip to main contentSkip to "About this site"Switch to basic HTML versionSearch and menusSearch and menusCanadian Institutesof Health ResearchYou are here:Home Initiatives Drug Safety and Effectiveness NetworkDSEN AbstractIs there an impact of sex (biologically male/female) differences between donors and recipients on safety and efficacy of cell therapies for immune system and autoimmune conditions?Other formatPDF version(192 KB)What is the current situation?Allogeneic and autologous hematopoietic stem cell transplantation (HSCT) has been increasingly used as a potentially life-saving treatment for severe autoimmune

Safety and immunogenicity of COVID-19 vaccines in pediatric populations with systemic immune-mediated diseases Skip to main contentSkip to "About this site"Switch to basic HTML versionSearch and menusSearch and menusCanadian Institutesof Health ResearchYou are here:Home Initiatives Drug Safety and Effectiveness NetworkDSEN AbstractSafety and Immunogenicity of COVID-19 Vaccines in Pediatric recommendations on COVID-19 vaccines supported the use of COVID-19 vaccines in adolescent and pediatric populations of this age. However, evidence on the safety or immunogenicity of COVID-19 vaccines in pediatric/adolescent populations with autoimmune diseases is lacking.SummaryCanada’s National Advisory Committee on Immunization (NACI) needs evidence on the safety and effectiveness of COVID-19 vaccines

Systematic review update on the efficacy, effectiveness and safety of newer and enhanced seasonal influenza vaccines for the prevention of laboratory confirmed influenza in individuals aged 18 years and over Manage cookiesCookiesWe use cookies to collect statistics on how the visitors navigate the website and to improve the user experience. Find out more on how we use cookies and how you can change your settings.I accept cookiesI don't accept cookiesRemind me laterSkip to main contentAn official EU websiteHow do you know?Global NavigationOther sites European Centre for Disease Prevention and ControlAn agency of the European UnionHome Systematic review update on the efficacy, effectiveness and safety of newer and enhanced seasonal influenza vaccines for the prevention of laboratory

Efficacy and safety of COVID-19 vaccines. Different forms of vaccines have been developed to prevent the SARS-CoV-2 virus and subsequent COVID-19 disease. Several are in widespread use globally.  OBJECTIVES: To assess the efficacy and safety of COVID-19 vaccines (as a full primary vaccination series or a booster dose) against SARS-CoV-2. We searched the Cochrane COVID-19 Study Register be generalized to pregnant women, individuals with a history of SARS-CoV-2 infection, or immunocompromized people. Most trials had a short follow-up and were conducted before the emergence of variants of concern. Implications for research Future research should evaluate the long-term effect of vaccines, compare different vaccines and vaccine schedules, assess vaccine efficacy and safety in specific populations

Efficacy, effectiveness and safety of HPV vaccination in women with conisation: a systematic review and meta-analyses Efficacy, effectiveness and safety of HPV vaccination in women with conisation: a systematic review and meta-analyses Skip to main content Global Navigation * Other sites * ECDC * European Antibiotic Awareness Day * ESCAIDE - Scientific conference * Eurosurveillance journal * EVIP - Vaccination portal European Centre for Disease Prevention and Control An agency of the European Union Search SearchSearch * Home * Infectious disease topics * Infectious disease topics * ABCDEFGHIJKLMNOPQRSTUVWXYZ * Related public health topics * Spotlight * Antimicrobial resistance (AMR) * Avian influenza * COVID-19 * Immunisation and vaccines * One Health * Pertussis (whooping cough) * * Ending

of adverse events following immunization (AEFIs) in Ontario • an explanation of data extraction and analytic methods used for the tool • technical notes on interpretation and limitations of AEFI surveillance data presented in the tool Canada’s Vaccine Safety System In Canada, vaccines are thoroughly reviewed for efficacy and safety prior to being approved for use. Following approval of a new vaccine be further evaluated.4 AEFIs reported to provincial and territorial public health authorities are reported to the Canadian Adverse Event Following Immunization Surveillance System (CAEFISS), maintained by PHAC. CAEFISS is a collaborative post-marketing surveillance system that continuously monitors the safety of vaccines in Canada. AEFI reports received by vaccine manufacturers may also be voluntarily

Covid-19 vaccines and current evidence related to their safety and effectiveness in people living with HIV COVID-19 VACCINES AND CURRENT EVIDENCE RELATED TO THEIR SAFETY AND EFFECTIVENESS IN PEOPLE LIVING WITH HIV | The Ontario HIV Treatment Network The Ontario HIV Treatment NetworkNavigation * HIV Evidence & Interventions * Rapid Responses * Request a Rapid Response * Reports the OHTN * OHTN Strategic Plan * Rapid Learning * Board of Directors * Executive Director * Work at the OHTN * Contact the OHTN * Staff Directory * Sign up for Did You Know * Read OHTN policies and operational reports * Accessibility policy * GIPA policy * SubscribeCOVID-19 VACCINES AND CURRENT EVIDENCE RELATED TO THEIR SAFETY

What is the effectiveness and safety of Respiratory Syncytial Virus (RSV) vaccination in older adults? Credits Earned (2023)LEARNSEARCH?HELPENGLISHFRANÇAISSign In Join NowMembershipAccount MembershipCredit HistoryEdit ProfileSign OutTools for Practice<< PreviousBack to Tools For Practice#354 – Preventing RSV in the elderlyCLINICAL QUESTIONWhat is the effectiveness and safety of Respiratory with advancing age, long-term care, and comorbidities like chronic kidney disease/COPD.9,12Risk of contracting influenza either 2-10x higher8,10-13 or similar to RSV.14US guidance recommends shared decision-making (aid available)15 for vaccinating ≥60.3Latest Tools for PracticeDanielle Perry RN MSc#354 - Preventing RSV in the elderly (Free)What is the effectiveness and safety of Respiratory Syncytial Virus

safety * Vaccine efficacy / effectiveness * Vaccination coverage * EU vaccination schedules * Immunisation Information Systems * European Immunisation Week * Communication * Communication guides on immunisation * Communication toolkit on immunisation * Communication research on immunisation COVID-19 vaccines two-to- three weeks before donation should be taken with caution.DownloadSuspected adverse reactions to COVID-19 vaccination and the safety of substances of human origin - EN - [PDF-558.79 KB] Erratum: On 8 June 2021, Column 3 of Table 2 “Deferral period after suspected adverse reaction (p.5) was changed from “–" to “2 days”. * * Coronavirus * COVID-19 * EU/EEA * Immunisation

Efficacy, Safety, and Immunogenicity of the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Respiratory Syncytial Virus Prefusion F Protein Vaccine Trial To evaluate descriptive efficacy data, exploratory immunogenicity data, and safety follow-up through study completion from the global, phase 3 MATISSE (Maternal Immunization Study for Safety and Efficacy) maternal and at vaccination, number of days from vaccination to delivery, country, maternal age). Final RSVpreF safety results in pregnant and newborn and infant participants were consistent with the primary analysis with no new safety concerns identified. This final analysis of MATISSE trial data confirms the primary analysis conclusions: Maternal vaccination with RSVpreF has a favorable safety profile in both pregnant

is the ChAdOx1/AZD1222 vaccine developed by the University of Oxford, which uses an extensively studied chimpanzee adenovirus vector.Some potential COVID-19 vaccines use conventional vaccine technology, based on viral protein administered with an adjuvant to trigger a response by the innate immune system.28There have been safety concerns surrounding adjuvants with previous vaccines29; whether Postmarketing studies: can they provide a safety net for COVID-19 vaccines in the UK? Skip to main contentSubscribe Log In Basket Search Latest content Current issue Archive Authors AboutYou are hereHome Archive Volume 27, Issue 1Email alertsArticleTextArticleinfoCitationToolsShareRapid ResponsesArticlemetricsAlertsPDFEBM analysisPostmarketing studies: can they provide a safety net for COVID-19

Safety of Vaccines Used for Routine Immunization in the United States: An Update Safety of Vaccines Used for Routine Immunization in the United States: An UpdateComparative Effectiveness ReviewNumber 244R Comparative Effectiveness Review Number 244 Safety of Vaccines Used for Routine Immunization in the United States: An Update Prepared for: Agency for Healthcare Research and Quality U.S on an evidence report, Safety of Vaccines Used for Routine Immunization in the United States: An Update, by the Evidence-based Practice Center Program at the Agency for Healthcare Research and Quality (AHRQ). Suggested citation: Gidengil C, Goetz MB, Maglione M, Newberry SJ, Chen P, O’Hollaren K, Qureshi N, Scholl K, Ruelaz Maher A, Akinniranye O, Kim TM, Jimoh O, Xenakis L, Kong W, Xu Z, Hall O, Larkin J

Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine targeting serogroups A, C, W, Y, and X when co-administered with routine childhood vaccines at ages 9 months and 15 months in Mali: a single-centre, double-blind, randomised, cont Invasive meningococcal disease is a devastating public health problem for the African meningitis belt. We assessed the safety completed their local infant Expanded Program on Immunization (EPI) vaccines were recruited at the Centre pour le Développement des Vaccins in Bamako, Mali. Participants were randomly assigned (1:1·2) at their 9-month EPI visits to receive a meningococcal vaccine at either their 9-month or 15-month EPI vaccination visits. At each participant's designated EPI visit, they were randomly assigned a second

Breadth of immune response, immunogenicity, reactogenicity, and safety for a pentavalent meningococcal ABCWY vaccine in healthy adolescents and young adults: results from a phase 3, randomised, controlled observer-blinded trial A multicomponent meningococcal serogroups ABCWY vaccine (MenABCWY) could provide broad protection against disease-causing meningococcal strains and simplify the immunisation schedule. The aim of this trial was to confirm the effect of the licensed meningococcal serogroup B (MenB) vaccine, 4CMenB, against diverse MenB strains, and to assess the breadth of immune response against a panel of 110 MenB strains for MenABCWY containing the antigenic components of 4CMenB and licensed serogroups ACWY vaccine, MenACWY-CRM, the non-inferiority of the immune response

Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine versus a quadrivalent meningococcal conjugate vaccine in adults in India: an observer-blind, randomised, active-controlled, phase 2/3 study Meningococcal disease remains an important public health problem globally. We assessed the non-inferiority and the lot-to-lot consistency of a pentavalent meningococcal ACYWX collected for 180 days, and assessed in the safety population (all participants who received vaccination). This study is registered with ClinicalTrials.gov, NCT04358731, and CTRI, CTRI/2019/12/022436, and is now complete. Between Dec 27, 2019, and Sept 19, 2020, 1712 individuals were screened, of whom 1640 were randomly assigned and received NmCV-5 (n=1233) or MenACWY-D (n=407; mean age 26·4 years [SD 12

to 4·7) for omicron BA.1. Coadministered mRNA-1345 plus SIIV4 or mRNA-1273.214 vaccines had acceptable safety profiles and elicited mostly non-inferior immune responses compared to individual vaccines in adults aged 50 years or older; only the seroresponse rate difference in nAbs against RSV-A in part A did not meet the non-inferiority criterion. Overall, these data support coadministration of mRNA Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 tria Coadministration of a respiratory syncytial virus (RSV) vaccine with seasonal influenza or SARS-CoV-2 vaccines could reduce health-care visits and increase vaccination uptake in older adults who

Immunogenicity and safety of measles-mumps-rubella vaccine delivered by the aerosol, intradermal and intramuscular routes in previously vaccinated young adults: a randomized controlled trial protocol. There are increasing reports of outbreaks of measles in countries that achieved measles elimination using two doses of measles-mumps-rubella (MMR) vaccine, particularly in health care settings . While responses to a third dose of MMR in two-dose recipients have been examined, these studies have all administered MMR by the standard (intramuscular or subcutaneous) route, and data on the duration of antibody are limited. We have developed a protocol for an open-label parallel-arm randomized-controlled trial to compare measles antibody responses and safety after intradermal and aerosol